Hennion & Walsh Asset Management, Inc. 2seventy Bio, Inc. Transaction History

Hennion & Walsh Asset Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	SELL	$3.14 - $11.2 $10,066 - $35,907	-3,206 Reduced 16.49%	16,238 $63,000
Q2 2023 Aug 09, 2023	SELL	$8.45 - $12.48 $118,426 - $174,907	-14,015 Reduced 41.89%	19,444 $197,000
Q1 2023 Apr 20, 2023	SELL	$9.21 - $14.98 $8,648 - $14,066	-939 Reduced 2.73%	33,459 $341,000
Q4 2022 Jan 12, 2023	BUY	$8.57 - $17.0 $29,369 - $58,259	3,427 Added 11.07%	34,398 $322,000
Q3 2022 Nov 14, 2022	SELL	$12.56 - $17.54 $9,859 - $13,768	-785 Reduced 2.47%	30,971 $451,000
Q2 2022 Jul 19, 2022	BUY	$10.55 - $18.81 $17,059 - $30,415	1,617 Added 5.37%	31,756 $419,000
Q1 2022 Apr 26, 2022	BUY	$11.67 - $26.72 $351,722 - $805,314	30,139 New	30,139 $514,000

126

45.6M

122K

19.8K

Ticker TSVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,873,600
Market Cap $150M
Description
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.